Exagen Shares Fall 33% After Third-Quarter Loss Misses Forecast

Exagen shares dropped 33% to $4.75 by midday Tuesday after the precision medicine company reported a third-quarter loss wider than analysts had forecast. The stock is down 22% this year, despite revenue growth from a year earlier.

November 10, 2026, 09:23 PM 461 0

Exagen reported a net loss of $6.3 million, or 25 cents a share, for the quarter, compared with a loss of $7.1 million, or 31 cents a share, a year earlier. Analysts polled by FactSet had expected a loss of 18 cents a share.

Revenue increased to $18.4 million from $17.2 million a year earlier, slightly above analysts’ estimate of $18.3 million.

The company reiterated its full-year revenue guidance of $72 million to $75 million. Analysts expect revenue of $73.9 million.

When reusing this material a link to Money Talk is required.

Comments (0)

No comments yet. Be the first!

Read Also

TriSalus Shares Drop 16% as Company Cuts Revenue Outlook

McEwen Shares Fall 18% as Quarterly Loss Widens

Ameresco Rises 16% After Earnings and Revenue Beat

FS Bancorp CFO Phillip Whittington to Move Into Accounting Role

Comments (0)

Leave a comment